Under their new collaboration and licence agreement, Novo Nordisk has obtained exclusive rights to develop and commercialize EraCal’s oral-active anti-obesity drug, a first-in-class appetite suppressor. In return, the Swiss startup is eligible for up to €235 million in payments. With its own weight-loss drug Wegovy, Novo Nordisk has become the most valuable company in Europe in 2023.
